Pacira BioSciences Inc
PCRXHealthcare|Drug Manufacturers - Specialty & Generic|USA
$25.47
-0.01 (-0.04%)
DCF (FCF)
$43.62
Tangible Book
$7.15
Graham Number
$18.67
Earnings Power
$19.49
Upcoming Data Readouts (10)
Oct 2026
Est. completion
NASpasticity, Cerebral or Spinal Condition
Study to Assess the Efficacy and Safety of Iovera®° System in Subjects With Upper Extremity Spasticity
NCT06340451n=132
Dec 2026
Est. completion
Dec 2026
Est. completion
NATotal Knee Arthroplasty
Effectiveness of Exparel Anesthetic Administered by the Surgeon During Knee Surgery
NCT06946368n=60
Jan 2027
Est. completion
P1Postoperative Pain
Study to Evaluate the Pharmacokinetics and Safety of EXPAREL for Postoperative Analgesia in Subjects Undergoing Cardiac Surgery
NCT06271265n=48
Apr 2027
Est. completion
NAACL Repair
The Effect of Pre-Operative Cryoneurolysis on Post-Operative Narcotic Consumption in Patients Undergoing Autograft ACL Reconstruction
NCT06603051n=20
Dec 2027
Est. completion
NASpasticity as Sequela of Stroke
Cryoneurolysis for Spasticity Treatment: Long-term Clinical Outcomes and Mechanisms in the Central Nervous System
NCT06958289n=25
May 2028
Est. completion
NALow Back Pain, Chronic
A Prospective Study to Evaluate the Efficacy of Iovera Lumbar Medial Branch Cryoneurolysis Versus Radiofrequency Ablation for the Treatment of Chronic Low Back Pain
NCT07214844n=110
Aug 2029
Est. completion
Jun 2032
Est. completion
Jul 2032
Est. completion
P2Osteoarthritis (OA) of the Knee
A Study to Assess Safety and Tolerability of PCRX-201 in Subjects With Painful Osteoarthritis of the Knee
NCT06884865n=135
Awaiting Results (1)
Trials past primary completion date but still active — data readout may be imminent.
Nov 2023
P1
Study to Evaluate the Safety and Tolerability of FX201 in Patients with Osteoarthritis of the Knee
NCT04119687